Skip to main content
Equibles
REPL logo

REPL · Replimune Group, Inc. · Metrics

Track REPL — free

Use REPL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research REPL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.99 +0.27 (+2.30%) At close · Oct 22
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 14, 2026

The latest filing states the doubt was alleviated.

“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.10B
Shares
94.22M
Volume · Oct 22 1.76M Avg daily vol (3M) 3.99M

REPL metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$11.99
Market cap
$1.10B

Price action

20 metrics
Price change (1W)
+2.0%
Price change (30D)
-11.0%
Price change (3M)
+14.6%
Price change (6M)
+320.7%
Price change (YTD)
+23.4%
Price change (1Y)
+44.5%
Trailing year
Price change (5Y)
-58.7%
52-week high
$15.98
52-week low
$1.70
Change from 52-week high
-25.0%
Change from 52-week low
+605.3%
Annualized volatility
186.7%
Annualized volatility (3M)
237.3%
Beta
2.2
RSI (14D)
44.9
Price vs SMA 50
-11.9%
Price vs SMA 200
+31.6%
Avg volume (3M)
3.99M
Relative volume
0.4
Average dollar volume
$46.61M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
94.22M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
10.5
reciprocal yield 9.6%
FCF yield
-25.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-26.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-28
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$297.74M
Net income (TTM)
−$297.01M
Trailing 12 months
Diluted EPS (TTM)
$-3.15
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.17
EBITDA per diluted share (TTM)
$-3.13
Net income per diluted share (TTM)
$-3.16
Operating cash flow per diluted share (TTM)
$-2.97
Free cash flow per diluted share (TTM)
$-2.98
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$2.26
Stock compensation per diluted share (TTM)
$0.33
Book value per share
$2.01

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-281.1%
Return on assets
-117.7%
Debt / equity
1.0
Current ratio
5.2
EBITDA (TTM)
−$294.35M
Free cash flow (TTM)
−$280.55M
Quick ratio
5.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$86.62M
Latest balance sheet
Cash & equivalents
$185.36M
Total assets
$252.45M
Total debt
$108.70M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$279.06M
Capital expenditures (TTM)
$1.49M
R&D (TTM)
$212.62M
SG&A (TTM)
$85.13M
Stock compensation (TTM)
$31.18M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
204
13F filer change QoQ
+16
Institutional ownership
110.4%
Conviction holders (share of 13F filers)
1.5%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.1%
Holder tenure
12.5
Price vs estimated holder cost
+20.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
14.0%

Short interest

3 metrics
Short interest
24.5%
Latest settlement · 10.8 days to cover
Days to cover
10.8d
Short-squeeze score
93 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.04M
Insider-sentiment score
19 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1737953 CUSIP 76029N106 13F (30d) 18 filings 18 filers Visit website Investor relations